396 related articles for article (PubMed ID: 37526149)
1. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
2. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
[TBL] [Abstract][Full Text] [Related]
3. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
[TBL] [Abstract][Full Text] [Related]
4. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J
Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038
[TBL] [Abstract][Full Text] [Related]
5. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F
J Clin Oncol; 2024 Apr; ():JCO2301909. PubMed ID: 38652877
[TBL] [Abstract][Full Text] [Related]
6. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
8. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A
Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525
[TBL] [Abstract][Full Text] [Related]
11. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
12. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
Schipilliti FM; Drittone D; Mazzuca F; La Forgia D; Guven DC; Rizzo A
Heliyon; 2024 Apr; 10(7):e28385. PubMed ID: 38560142
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
16. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
